Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

LivaNova PLC

Healthcare US LIVN

73.72USD
2.39(3.35%)

Last update at 2026-06-04T20:00:00Z

Day Range

72.1375.05
LowHigh

52 Week Range

42.7564.47
LowHigh

Fundamentals

  • Previous Close 71.33
  • Market Cap3225.28M
  • Volume573224
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA149.05M
  • Revenue TTM1185.04M
  • Revenue Per Share TTM21.93
  • Gross Profit TTM 696.73M
  • Diluted EPS TTM-0.6

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -75.10000M -124.50000M -344.00000M -185.70000M -247.40000M
Minority interest - - - - -
Net income -86.20000M -135.70000M -343.30000M -155.50000M -189.40000M
Selling general administrative 469.24M 471.90M 427.77M 506.54M 462.41M
Selling and marketing expenses - - - - -
Gross profit 707.20M 706.00M 618.20M 744.80M 734.50M
Reconciled depreciation 57.80M 67.90M 81.32M 82.99M 69.94M
Ebit 52.70M -0.90000M -42.80000M 48.00M 86.30M
Ebitda 110.50M 67.00M 38.50M 131.00M 156.20M
Depreciation and amortization 57.80M 67.90M 81.30M 83.00M 69.90M
Non operating income net other - -59.95100M -0.13300M - 11.69M
Operating income 52.70M -0.90000M -42.80000M 48.00M -248.10000M
Other operating expenses 969.10M 1036.20M 977.20M 1036.20M 1020.70M
Interest expense 48.30M 49.70M 40.70M 14.30M 9.00M
Tax provision 11.05M 11.20M -0.70000M -30.15300M -69.62900M
Interest income 4.70M 0.43M 0.13M 0.80M 0.85M
Net interest income -43.55300M -49.70000M -40.70000M -14.28800M -8.97800M
Extraordinary items - - - 0.36M -10.93700M
Non recurring - - 227.00M - 334.36M
Other items - - - - -
Income tax expense 11.10M 11.20M -0.70000M -30.20000M -69.60000M
Total revenue 1021.80M 1035.40M 934.20M 1084.20M 1107.00M
Total operating expenses 654.50M 706.80M 661.20M 696.80M 648.20M
Cost of revenue 314.60M 329.40M 316.00M 339.40M 372.50M
Total other income expense net -127.80000M -123.60000M -301.20000M -233.70000M -324.70000M
Discontinued operations - - -1.50000M 0.36M -10.93700M
Net income from continuing ops -86.24600M -135.80000M -343.25100M -155.54100M -178.46200M
Net income applicable to common shares -86.24600M -135.80000M -345.00800M -155.17600M -189.39900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2429.56M 2294.80M 2201.00M 2411.40M 2411.80M
Intangible assets 261.18M 368.60M 399.70M 437.60M 607.50M
Earning assets - - - - -
Other current assets 47.33M 25.00M 35.80M 24.80M 28.50M
Total liab 1151.93M 1087.20M 906.40M 1292.60M 1028.10M
Total stockholder equity 1277.63M 1207.60M 1294.60M 1118.80M 1383.70M
Deferred long term liab - - - 130.85M -
Other current liab 216.94M 189.47M 390.88M 215.17M 342.57M
Common stock 82.53M 82.42M 82.30M 76.30M 76.26M
Capital stock 82.53M 82.42M 82.30M 76.30M 76.26M
Retained earnings -966.48400M -984.03000M -897.78400M -752.40200M -406.75500M
Other liab - 242.14M 163.70M 299.00M 209.11M
Good will 782.94M 768.80M 899.50M 922.30M 915.80M
Other assets - 72.01M 15.30M 0.20M -0.10000M
Cash 577.87M 214.20M 208.00M 252.80M 61.10M
Cash and equivalents - - - - -
Total current liabilities 334.98M 297.40M 697.00M 309.10M 512.60M
Current deferred revenue 10.72M 10.23M 8.42M 6.93M 6.73M
Net debt 62.53M 356.80M 67.40M 445.00M 322.60M
Short term debt 26.47M 23.40M 229.70M 13.30M 77.40M
Short long term debt 18.11M 23.43M 229.70M 13.30M 77.40M
Short long term debt total 640.40M 571.00M 275.40M 697.80M 383.70M
Other stockholder equity 2189.46M 2157.32M 2117.27M 1767.09M 1733.59M
Property plant equipment - 183.02M 190.70M 163.81M 235.73M
Total current assets 988.16M 886.10M 679.20M 719.40M 549.40M
Long term investments 22.84M 16.27M 16.60M 103.40M 27.26M
Net tangible assets - 70.28M -4.60000M -241.12500M -139.62300M
Short term investments - -0.03400M -0.00200M 31.09M -
Net receivables 215.07M 183.10M 185.40M 184.40M 257.80M
Long term debt 568.54M 518.07M 9.80M 642.30M 260.33M
Inventory 147.89M 129.40M 105.80M 126.70M 164.20M
Accounts payable 80.84M 74.30M 68.00M 73.70M 85.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -27.88300M -48.11900M -7.17700M 27.81M -19.39200M
Additional paid in capital - - - - -
Common stock total equity - - 82.30M 76.30M 76.26M
Preferred stock total equity - - - - -
Retained earnings total equity - - -897.78400M -752.40200M -
Treasury stock - - -0.65000M -1.03400M -1.26300M
Accumulated amortization - - - - -
Non currrent assets other 12.06M 70.60M 13.10M 83.50M 7.40M
Deferred long term asset charges - - - - -
Non current assets total 1441.40M 1408.70M 1521.80M 1691.80M 1862.50M
Capital lease obligations 53.75M 38.93M 35.90M 42.20M 57.14M
Long term debt total - - - 642.30M 260.33M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -38.41400M 19.40M -5.87500M -41.29000M -3.77000M
Change to liabilities -3.51000M 13.00M 2.67M -38.57700M 13.68M
Total cashflows from investing activities -38.41400M 36.90M -41.84400M -41.29000M -120.55600M
Net borrowings 284.01M -487.90000M 339.35M 171.76M 59.74M
Total cash from financing activities 280.10M -181.50000M 310.80M 146.60M -42.30000M
Change to operating activities 0.93M 27.40M -173.90000M -125.77200M 287.58M
Net income -86.20000M -135.80000M -345.00000M -155.20000M -189.40000M
Change in cash 307.60M -44.80000M 191.70M 13.90M -46.40000M
Begin period cash flow 208.00M 252.80M 61.10M 47.20M 93.60M
End period cash flow 515.60M 208.00M 252.80M 61.10M 47.20M
Total cash from operating activities 69.90M 102.50M -79.40000M -91.10000M 120.50M
Issuance of capital stock 0.00000M 322.56M - - -
Depreciation 57.80M 67.90M 81.30M 83.00M 69.90M
Other cashflows from investing activities -0.08800M 1.80M -0.94500M -1.32100M -78.78900M
Dividends paid - - - - -
Change to inventory -25.70000M 4.50M 1.40M -10.60000M -10.60000M
Change to account receivables -4.80000M -15.70000M 58.80M -5.30000M 21.20M
Sale purchase of stock -8.70000M -12.90000M -5.60000M -7.10000M -61.60000M
Other cashflows from financing activities 512.30M -3.30000M 844.20M 179.10M 333.80M
Change to netincome 108.73M 124.40M 261.35M 167.56M -80.56400M
Capital expenditures 26.50M 25.50M 35.00M 28.00M 38.00M
Change receivables - -15.74500M 58.80M - 21.18M
Cash flows other operating - 63.88M -137.85500M - 282.93M
Exchange rate changes - - - - -3.99600M
Cash and cash equivalents changes - -42.03500M 189.49M - -46.41100M
Change in working capital -31.70000M 26.00M -111.00000M -58.20000M 4.80M
Stock based compensation 44.80M 40.60M 35.10M 32.60M 26.90M
Other non cash items 83.80M 100.90M 222.90M 33.00M 303.40M
Free cash flow 43.40M 77.00M -114.40000M -119.10000M 82.50M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LIVN
LivaNova PLC		 2.39 3.35% 73.72 - 27.17 2.48 2.24 2.80 84.04
ABT
Abbott Laboratories		 3.79 4.36% 90.78 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 6.21 2.11% 301.21 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 3.98 5.11% 81.93 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.16 2.43% 48.85 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LivaNova PLC

20 Eastbourne Terrace, London, United Kingdom, W2 6LG

Key Executives

Name Title Year Born
Mr. Damien McDonald CEO & Director 1965
Mr. Alex Shvartsburg Chief Financial Officer 1971
Ms. Trui Hebbelinck Chief HR Officer 1972
Ms. Keyna Pidcock Skeffington Sr. VP, Special Advisor & Exec. Officer 1963
Mr. Marco Dolci Pres of Cardiopulmonary Bus. Unit 1962
Lindsey Little Sr. Director of Investor Relations NA
Mr. Michael Hutchinson Sr. VP, Chief Legal Officer and Company Sec. NA
Deanna Wilke VP of Corp. Communications NA
Mr. Matthew Joseph Dodds III Sr. VP of Corp. Devel. NA
Dr. Bryan D. Olin Ph.D. Sr. VP & Head of Product Devel. - Neuromodulation 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions